Stockreport

Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine

Altimmune, Inc.  (ALT) 
NASDAQ:AMEX Investor Relations: altimmune.com/investors
PDF GAITHERSBURG, Md., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the advancement of a no [Read more]